Streetbeat News

Products Services

BTAI

The U.S. Patent and Trademark Office has allowed a patent application for BioXcel Therapeutics' BXCL501, a treatment for agitation in Alzheimer's patients. The patent covers various formulations and is expected to expire on Dec. 29, 2037, with potential adjustments.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:05 pm

BMY

TSVT

The FDA's Oncologic Drugs Advisory Committee is set to review Bristol Myers Squibb and 2Seventy Bio's supplemental application for Abecma, aimed at treating triple-class exposed relapsed or refractory multiple myeloma, in a virtual meeting on March 15.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 12:02 pm

TM

Toyota Motor Co (NYSE:TM) has clarified its stance on electric vehicles (EVs), stating that while it is not anti-EV, it does not view EVs as the sole solution to achieving carbon neutrality. The company is committed to a diversified strategy that includes battery electric vehicles (BEVs), hybrids, and potentially hydrogen fuel cell vehicles. This comes amid criticism from organizations like Greenpeace for Toyota's slow EV adoption and continued diesel production. Toyota's approach to environmental sustainability and its impact on the EV market share has been a topic of debate.

Portfolio Pulse from Benzinga Neuro

February 05, 2024 | 11:56 am

NRXP

NRx Pharmaceuticals announced the creation of Hope Therapeutics to focus on NRX-100 (now HTX-100), aimed at treating suicidal depression. NRx and its shareholders will own the new company, receiving shares as a dividend plus a royalty coupon on HTX-100 sales, pending Board approval. The arrangement is structured to avoid taxation for shareholders.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 11:52 am

HBB

Hamilton Beach Brands Holding Company (HBB) has acquired HealthBeacon PLC, a medical technology firm. This move is part of HBB's strategy to expand in the home health and wellness market. HealthBeacon, known for developing connected devices for managing injectable medication for chronic conditions at home, was already a strategic partner of HBB. The financial terms of the acquisition were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 11:37 am

WWR

Westwater Resources, Inc. (WWR) has entered into its first off-take agreement with SK On Co., Ltd., a leading EV battery manufacturer. Under this agreement, Westwater will supply CSPG-10 natural graphite anode products from its Kellyton Graphite Plant in Alabama to SK On's U.S. battery plants. The agreement specifies a minimum purchase amount of the product by SK On, which is tied to a percentage of SK On's forecasted volume requirement, potentially increasing by mutual consent.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 11:36 am

CTLT

NVO

Novo Nordisk has agreed to acquire three fill-finish sites from Novo Holdings as part of a transaction related to Novo Holdings' acquisition of Catalent, Inc. for $11B. These sites, located in Italy, Belgium, and the US, are specialized in sterile drug filling and employ over 3,000 people. This acquisition aligns with Novo Nordisk's strategy to expand its manufacturing capacity to support its diabetes and obesity treatments, with expected capacity increases from 2026.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 11:11 am

PINS

Pinterest, Inc. (NYSE:PINS) received a 30% price target increase from KeyBanc Capital Markets, raising it from $37 to $48, ahead of its Q4 earnings release. Analyst Justin Patterson maintained an Overweight rating, citing expected solid Q4 performance with 14% revenue growth and potential for 15-17% future growth. Factors contributing to the positive outlook include a strong ad market, product innovation, and partnerships. Patterson also anticipates EBITDA to be 4% above consensus at $370 million, driven by recent expense efficiencies.

Portfolio Pulse from Shanthi Rexaline

February 05, 2024 | 10:55 am

GRFS

Grifols, a leading producer of plasma-derived medicines, announced the launch of 4- and 5-gram vials of PROLASTIN for alpha1-antitrypsin deficiency therapy, reinforcing its position in the market for this treatment.

Portfolio Pulse from Charles Gross

February 05, 2024 | 10:39 am

AAPL

The release of Apple Inc.'s (NASDAQ:AAPL) mixed-reality headset, Apple Vision Pro, has sparked excitement among buyers showcasing its capabilities through social media. Demonstrations include multitasking with virtual screens for work, entertainment, and cooking, deepfake interactions, gamified chores, immersive sports viewing, enhanced YouTube experiences, realistic Fruit Ninja gameplay, simultaneous sports watching, piano lessons without a piano, and 3D modeling. These early showcases highlight the potential transformative impact of Apple Vision Pro on daily activities and entertainment.

Portfolio Pulse from Rounak Jain

February 05, 2024 | 10:26 am